0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CEACAM-1

CEACAM-1

Brief Information

Name:Carcinoembryonic antigen related cell adhesion molecule 1
Target Synonym:CEACAM1,Biliary glycoprotein 1,BGP,CD66a,Carcinoembryonic Antigen Related Cell Adhesion Molecule 1,CD66a Antigen,BGP1,Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1,Antigen CD66,BGP-1,BGPI,CEA Cell Adhesion Molecule 1,Carcinoembryonic Antigen-R
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:0
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
Cat. No. Species Product Description Structure Purity Feature
CE1-H82E5 Human Biotinylated Human CEACAM-1 / CD66a Protein, Avitag™,His Tag
CE1-H82E5-structure
CE1-H82E5-sds
CE1-H82E5-elisa_1
CE1-H5220 Human Human CEACAM-1 / CD66a Protein, His Tag
CE1-H5220-structure
CE1-H5220-sds
CE1-H5220-elisa_1

Part of Bioactivity data

CE1-H5220-ELISA
Human CEACAM-1, His TagHuman CEACAM-1, His Tag (Cat. No. CE1-H5220) ELISA bioactivity

Immobilized Human CEACAM-1, His Tag (Cat. No. CE1-H5220) at 10 μg/mL (100 μL/well) can bind Biotinylated Human CEACAM-8, His,Avitag (Cat. No. CE8-H82E9) with a linear range of 0.039-1.25 μg/mL (QC tested).

CE1-H82E5-ELISA
Biotinylated Human CEACAM-1, Avitag,His TagBiotinylated Human CEACAM-1, Avitag,His Tag (Cat. No. CE1-H82E5) ELISA bioactivity

Immobilized Human CD209, His Tag (Cat. No. CD9-H5246) at 5 μg/mL (100 μL/well) can bind Biotinylated Human CEACAM-1, Avitag,His Tag (Cat. No. CE1-H82E5) with a linear range of 10-78 ng/mL (QC tested).

Synonym Name

CEACAM1,CD66a,BGP,BGP1,BGPI

Background

Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) is also known as Biliary glycoprotein 1 (BGP1), CD66a, which belongs to the immunoglobulin superfamily or CEA family. CEACAM1 /CD66a contains three Ig-like C2-type (immunoglobulin-like) domains and one Ig-like V-type (immunoglobulin-like) domain. CEACAM1 /CD66a was described as an adhesion molecule mediating cell adhesion via both homophilic and heterophilic manners, and was detected on leukocytes, epithelia, and endothelia. Studies have revealed that CEACAM1 / BGP-1 performs actions in multiple cellular processes including tissue differentiation, angiogenesis, apoptosis, metastasis, as well as the modulation of innate and adaptive immune responses.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
CM-24 CM-24; MK-6018 Phase 2 Clinical Merck Sharp & Dohme Corp Ovarian Neoplasms; Solid tumours; Stomach Neoplasms; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Thyroid Cancer, Papillary Details

This web search service is supported by Google Inc.

totop